Model driven optimization of antiangiogenics + cytotoxics combination: application to breast cancer mice treated with bevacizumab + paclitaxel doublet leads to reduced tumor growth and fewer metastasis

Bevacizumab is the first-in-class antiangiogenic drug and is almost always administrated in combination with cytotoxics. Reports have shown that bevacizumab could induce a transient phase of vascular normalization, thus ensuring a better drug delivery when cytotoxics administration is adjuvant. Howe...

Descripción completa

Detalles Bibliográficos
Autores principales: Mollard, Severine, Ciccolini, Joseph, Imbs, Diane-Charlotte, Cheikh, Raouf El, Barbolosi, Dominique, Benzekry, Sebastien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5410287/
https://www.ncbi.nlm.nih.gov/pubmed/28416742
http://dx.doi.org/10.18632/oncotarget.15484

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5410287/
https://www.ncbi.nlm.nih.gov/pubmed/28416742
http://dx.doi.org/10.18632/oncotarget.15484

Ejemplares similares